CSPC PHARMA (01093.HK): Phase I Trial of SYH2083 Eye Drops for Dry Eye Disease Launched in China

NewTimeSpace News: On 20 October 2026, CSPC Pharmaceutical Group Limited (the "Company") voluntarily announced that the Phase I clinical trial (SYH2083-001) of SYH2083 eye drops (the "product"), developed by the Group for the treatment of dry eye disease, has officially been launched in China.

The announcement disclosed that the product is a dual-target inhibitor of lymphocyte function-associated antigen-1 (LFA-1) and reactive aldehyde species (RASP), capable of inhibiting the interaction between LFA-1 and intercellular adhesion molecule-1 (ICAM-1), reducing LFA-1-mediated cell adhesion while efficiently scavenging reactive aldehyde species. The product is expected to exert synergistic LFA-1 and RASP dual-target effects, overcoming the safety and efficacy limitations of single-target drugs and thereby offering dry eye patients a potentially better treatment option.

The Company stated that SYH2083-001 is a single-centre, randomised, double-blind, placebo-controlled and dose-escalation Phase I clinical trial conducted in healthy participants in China, designed to evaluate the safety, tolerability and pharmacokinetic profile of the product after single and multiple dosing. Participant recruitment and screening for the trial are currently being actively advanced.